Rheumatoid Arthritis Market

Market Overview:

The 7 major rheumatoid arthritis markets reached a value of US$ 27.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 33.8 Billion by 2034, exhibiting a growth rate (CAGR) of 1.88% during 2024-2034.

The rheumatoid arthritis market has been comprehensively analyzed in IMARC's new report titled "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rheumatoid arthritis refers to a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and stiffness. In this condition, the body's immune system mistakenly attacks the synovial membrane, which lines the joints, resulting in inflammation, thickening of the synovium, and damage to the surrounding cartilage and bone. The most common symptoms are joint pain, stiffness, and swelling, which can be present in multiple joints and may worsen in the morning or after periods of inactivity. As the disease progresses, joints may become deformed, limiting mobility. The ailment can also affect other body parts, such as the lungs, eyes, heart, etc. The diagnosis of rheumatoid arthritis typically involves a combination of physical examination, medical history, blood tests, and imaging procedures. The physical exam includes assessing joint mobility, checking for swelling or tenderness, and looking for other signs of inflammation. Several blood tests are performed to look for specific antibodies and inflammatory markers. Numerous imaging studies, such as X-rays and ultrasounds, are also used to assess joint damage and monitor disease progression.

The rising cases of immune system dysfunction, which leads to inflammation, pain, and damage to the joints, are primarily driving the rheumatoid arthritis market. In addition to this, the increasing prevalence of associated risk factors, such as genetic predisposition, excessive smoking, exposure to certain pollutants, infections, etc., is further bolstering the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen, for reducing inflammation and swelling in the joints is also creating a positive outlook for the market. Additionally, the ongoing advancements in the field of biomarker research are leading to the development of more accurate and sensitive tests for the ailment, such as anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) tests. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the inflating demand for disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, leflunomide, etc., which aid in slowing down the progression of the ailment by suppressing the immune system's attack on the joints, is expected to drive the rheumatoid arthritis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the rheumatoid arthritis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for rheumatoid arthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rheumatoid arthritis market in any manner.

Recent Developments:

• In November 2023, Aclaris Therapeutics, Inc. revealed the top-line results of a Phase 2b study of zunsemetinib (ATI-450), an experimental oral MK2 inhibitor, in participants with moderate to severe rheumatoid arthritis.
• In May 2023, The New England Journal of Medicine published detailed results from Eli Lilly and Company's phase 2a research of peresolimab in rheumatoid arthritis, in which peresolimab met the primary efficacy endpoint and had comparable rates of adverse events in the peresolimab and placebo arms. These findings provide the first clinical evidence that activating the endogenous PD-1 inhibitory pathway could be an effective treatment for rheumatologic illness.
• In April 2023, SynAct Pharma declared that it had completed patient recruitment for its Phase 2b clinical trial EXPAND, which is assessing its main drug AP1189 in patients with early rheumatoid arthritis who have substantial disease activity.

Key Highlights:

• Rheumatoid arthritis is estimated to impact around 0.24-1% of the population.
• The annual incidence of rheumatoid arthritis in the U.S. and northern European countries is reported to be around 40 per 100,000 people.
• Rheumatoid arthritis predominantly impacts women, with incidence and prevalence rates twice as high as in men. The lifetime chance of having rheumatoid arthritis is 3.6% in women and 1.7% in men.
• Rheumatoid arthritis is substantially more common in some populations, such as the Pima Native Americans, whose rates are up to ten times higher than those of most population groups.
• According to WHO, 13 million persons with rheumatoid arthritis have moderate or severe symptoms that could benefit from rehabilitation.

Drugs:

OLUMIANT (baricitinib) is approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more tumor necrosis factor (TNF) antagonist treatments. It is a once-daily medication that works by inhibiting JAK enzymes in patients.

ATI-450 is a potential oral inhibitor of mitogen-activated protein kinase 2 (MK2). This method may suppress numerous cytokines, chemokines, matrix metalloproteases, and other inflammatory signals. Aclaris is researching ATI-450 as a possible therapy for rheumatoid arthritis and other immuno-inflammatory illnesses.

Dekavil (F8IL10) is a fully human anti-inflammatory medication composed of the F8 antibody combined with interleukin-10 (IL10). The fusion with the F8 antibody, which is specific to the EDA domain of fibronectin, results in a product that selectively localizes in the inflamed tissue of diverse inflammatory diseases.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the rheumatoid arthritis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the rheumatoid arthritis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current rheumatoid arthritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of
marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the rheumatoid arthritis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the rheumatoid arthritis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the rheumatoid arthritis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of rheumatoid arthritis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with rheumatoid arthritis across the seven major markets?
• What is the size of the rheumatoid arthritis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of rheumatoid arthritis?
• What will be the growth rate of patients across the seven major markets?
   

Rheumatoid Arthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for rheumatoid arthritis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rheumatoid arthritis market?
• What are the key regulatory events related to the rheumatoid arthritis market?
• What is the structure of clinical trial landscape by status related to the rheumatoid arthritis market?
• What is the structure of clinical trial landscape by phase related to the rheumatoid arthritis market?
• What is the structure of clinical trial landscape by route of administration related to the rheumatoid arthritis market?